← Back to Search

Angiotensin Receptor-Neprilysin Inhibitor

Intervention for Heart Failure

Phase 4
Waitlist Available
Research Sponsored by Oslo University Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights

Study Summary

The study measure multiple neurohormones in patients with heart failure being treated with Sacubitril/Valsartan in increasing doses over an 8 week period.

Eligible Conditions
  • Heart Failure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Neurohormonal plasma concentration

Trial Design

1Treatment groups
Experimental Treatment
Group I: InterventionExperimental Treatment1 Intervention
Increasing doses of Sacubitril/Valsartan
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sacubitril
FDA approved

Find a Location

Who is running the clinical trial?

Oslo University HospitalLead Sponsor
1,081 Previous Clinical Trials
7,802,998 Total Patients Enrolled
11 Trials studying Heart Failure
2,376 Patients Enrolled for Heart Failure
Christian Hall, MD PhDStudy ChairUniversity of Oslo
~6 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top